Drug Profile
Research programme: tuberculosis therapies - Pfizer/Global Alliance for TB Drug Development
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals; Global Alliance for TB Drug Development
- Developer Anacor Pharmaceuticals; Global Alliance for TB Drug Development; GSK
- Class Small molecules
- Mechanism of Action Leucyl-tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Tuberculosis in USA
- 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
- 09 Oct 2012 Research is ongoing in USA